Big Pharma is slowly prepping us for the inevitable admission that serotonin is really not that good for us. Of course, it will not happen publicly but through the approval of drugs that block serotonin and promote dopamine activity. This news piece shows that the drug terguride (a lisuride derivative) is currently in a large scale human trial after being PROVEN to reverse symptoms of systemic sclerosis (also known as scleroderma).
I posted a study some time ago showing that drugs like lisuride are effective treatment for fibrosis of some organs.
Cyproheptadine, LSD-based Drugs Can Regenerate Damaged Liver
Even today, the official position on fibrotic diseases like systemic sclerosis is that they are uncurable, but apparently behind the scenes the truth is different.
Phase 3 Trial to Begin for Terguride in Diffuse Cutaneous Scleroderma - Scleroderma News
The German pharmaceutical company Medac, in August, will begin Phase 3 of a clinical trial to access the therapeutic potential of terguride, a disease-modifying drug for the treatment of diffuse cutaneous systemic sclerosis.
"...Terguride is a serotonin receptor blocker, acting at two particular serotonin receptors called 5-HT2A and 5-HT2B. Medac is convinced that stopping the nerve signaling in serotonin neurons will block the progression of fibrotic tissue development and blood vessel remodeling in organs affected by diffuse cutaneous systemic sclerosis. The antifibrotic effects of terguride were recently discovered and since proven in a pilot study of diffuse cutaneous systemic sclerosis patients."
"...In a press release provided to Scleroderma News, TERGISS principal investigator, Dr. Oliver Distler of the University Hospital Zurich, said no licensed medicine shown to have a genuine effect on the disease progression of diffuse cutaneous systemic sclerosis – yet."
I posted a study some time ago showing that drugs like lisuride are effective treatment for fibrosis of some organs.
Cyproheptadine, LSD-based Drugs Can Regenerate Damaged Liver
Even today, the official position on fibrotic diseases like systemic sclerosis is that they are uncurable, but apparently behind the scenes the truth is different.
Phase 3 Trial to Begin for Terguride in Diffuse Cutaneous Scleroderma - Scleroderma News
The German pharmaceutical company Medac, in August, will begin Phase 3 of a clinical trial to access the therapeutic potential of terguride, a disease-modifying drug for the treatment of diffuse cutaneous systemic sclerosis.
"...Terguride is a serotonin receptor blocker, acting at two particular serotonin receptors called 5-HT2A and 5-HT2B. Medac is convinced that stopping the nerve signaling in serotonin neurons will block the progression of fibrotic tissue development and blood vessel remodeling in organs affected by diffuse cutaneous systemic sclerosis. The antifibrotic effects of terguride were recently discovered and since proven in a pilot study of diffuse cutaneous systemic sclerosis patients."
"...In a press release provided to Scleroderma News, TERGISS principal investigator, Dr. Oliver Distler of the University Hospital Zurich, said no licensed medicine shown to have a genuine effect on the disease progression of diffuse cutaneous systemic sclerosis – yet."
Last edited: